米力农治疗心力衰竭的临床研究

摘要

目的 观察米力农治疗心力衰的临床效果及安全性.方法 选取我科自2007年1月至2011年6月期间收治的心力衰竭患者105例,按入院单双号将患者随机分为两组,观察组(52例)和对照组(53例),所有患者均采取使用利尿剂、口服血管紧张素转换酶抑制药等常规治疗,观察组患者在常规治疗基础上采用米力农治疗,对照组患者在常规治疗基础上采用硝普钠和多巴胺治疗,对观察组患者治疗前后心率(HR)、平均动脉压(MAP)及左室功能各项指标进行比较,同时比较观察组与对照组两组治疗效果.结果 观察组患者总有效率为71.15%,对照组患者总有效率为52.63%,两组差异显著,差异有统计学意义(P<0.05);观察组患者治疗后每博量(CO)、左心室射血分数(LVEF)、左室收缩期腔径(LVESD)、左室舒张期腔径(LVEDD)、心尖瓣双峰比值(E/A)较治疗前显著改善,差异均有统计学意义(P<0.05);观察组患者治疗前后HR及MAP无明显变化(P＞0.05).结论 米力农治疗心力衰竭临床效果显著,治疗时注意控制用药量及用药时间,可最大限度地确保用药安全,可作为心力衰竭患者理想的治疗方式之一.%Objective: To observe the clinical effect and security of milrinone in the treatment of heart failure. Method: Selected 105 patients treated in our department from Jan. 2007 to Jun. 2011 and they were randomly divided into two groups according to the hospital number, 52 cases in the observation group and 53 cases in the control group. All patients received the routine treatment of diuretics and oral taking of angiotensin converting enzyme, while patients in the observation group received the treatment of milrinone, and those in the control group received the treatment of sodium nitroprusside and dopamine. Compared the indicators of heart rate ( HR ), mean artery pressure ( MAP ) and left ventricular function on patients in the observation group before and after the treatment; meanwhile compared the curative effect between the observation group and control group. Result: The total effective rate of patients in the observation was 71. 15% , while the one of patients in the control group was 52. 63% , There's statistically significant difference ( P<0. 05 ); there was significant improvements on the cardiac output ( CO ), left ventricular ejection fraction ( LVEF ), left ventricular end - systolic diameter ( LVESD ), left ventricular end - diastolic diameter ( LVEDD ), and ratio of the E peak and A peak velocities ( E/A ) after the treatment than ones before the treatment, with the statistical difference ( P<0. 05 ); there was no significant difference in HR and MAP of patients in the observation group before and after the treatment ( P>0. 05 ). Conclusion: There is a significant clinical effect of milrinone in the treatment of heart failure. It should pay attention to the dosage and medication time during the treatment to maximally guarantee the security of the medication. It can be one ofthe most ideal treatments for heart failure.